Literature DB >> 12393514

Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis.

Niels-Bjarne Woods1, Arne Muessig, Manfred Schmidt, Johan Flygare, Karin Olsson, Patrick Salmon, Didier Trono, Christof von Kalle, Stefan Karlsson.   

Abstract

Efficient vector transduction of hematopoietic stem cells is a requirement for successful gene therapy of hematologic disorders. We asked whether human umbilical cord blood CD34(+)CD38(lo) nonobese diabetic/severe combined immunodeficiency (NOD/SCID) repopulating cells (SRCs) could be efficiently transduced using lentiviral vectors, with a particular focus on the average number of vector copies integrating into these primitive progenitor cells. Mouse bone marrow was analyzed by fluorescence-activated cell-sorter scanner and by semiquantitative polymerase chain reaction (PCR) to determine the transduction efficiency into SRCs. Lentiviral vector transduction resulted in an average of 22% (range, 3%-90%) of the human cells expressing green fluorescent protein (GFP), however, multiple vector copies were present in human hematopoietic cells, with an average of 5.6 +/- 3.3 (n = 12) copies per transduced cell. To confirm the ability of lentiviral vectors to integrate multiple vector copies into SRCs, linear amplification mediated (LAM)-PCR was used to analyze the integration site profile of a selected mouse showing low-level engraftment and virtually all human cells expressing GFP. Individually picked granulocyte macrophage colony-forming unit colonies derived from the bone marrow of this mouse were analyzed and shown to have the same 5 vector integrants within each colony. Interestingly, one integration site of the 5 that were sequenced in this mouse was located in a known tumor-suppressor gene, BRCA1. Therefore, these findings demonstrate the ability of lentiviral vectors to transduce multiple copies into a subset of NOD/SCID repopulating cells. While this is efficient in terms of transduction and transgene expression, it may increase the risk of insertional mutagenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393514     DOI: 10.1182/blood-2002-07-2238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

2.  Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

Authors:  Michael D Mühlebach; Isabel Schmitt; Stefanie Steidl; Jörn Stitz; Matthias Schweizer; Thomas Blankenstein; Klaus Cichutek; Wolfgang Uckert
Journal:  J Mol Med (Berl)       Date:  2003-10-24       Impact factor: 4.599

3.  Forward RNAi screens in primary human hematopoietic stem/progenitor cells.

Authors:  Nicole Ali; Christine Karlsson; Marie Aspling; Guang Hu; Nir Hacohen; David T Scadden; Jonas Larsson
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

4.  What is the future for cord blood stem cells?

Authors:  E A de Wynter
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

5.  Reducing the genotoxic potential of retroviral vectors.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2008

6.  Nongenetic method for purifying stem cell-derived cardiomyocytes.

Authors:  Fumiyuki Hattori; Hao Chen; Hiromi Yamashita; Shugo Tohyama; Yu-Suke Satoh; Shinsuke Yuasa; Weizhen Li; Hiroyuki Yamakawa; Tomofumi Tanaka; Takeshi Onitsuka; Kenichiro Shimoji; Yohei Ohno; Toru Egashira; Ruri Kaneda; Mitsushige Murata; Kyoko Hidaka; Takayuki Morisaki; Erika Sasaki; Takeshi Suzuki; Motoaki Sano; Shinji Makino; Shinzo Oikawa; Keiichi Fukuda
Journal:  Nat Methods       Date:  2009-11-29       Impact factor: 28.547

7.  Does retroviral insertional mutagenesis play a role in the generation of induced pluripotent stem cells?

Authors:  Robert G Hawley
Journal:  Mol Ther       Date:  2008-08       Impact factor: 11.454

8.  Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes.

Authors:  Brittni A Smith; Dawne N Shelton; Collin Kieffer; Brett Milash; Jerry Usary; Charles M Perou; Philip S Bernard; Bryan E Welm
Journal:  Genes Cancer       Date:  2012-09

9.  Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.

Authors:  Michael R Greene; Timothy Lockey; Perdeep K Mehta; Yoon-Sang Kim; Paul W Eldridge; John T Gray; Brian P Sorrentino
Journal:  Hum Gene Ther Methods       Date:  2012-11-07       Impact factor: 2.396

10.  Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression.

Authors:  Alice T Trinh; Bret G Ball; Erin Weber; Timothy K Gallaher; Zoya Gluzman-Poltorak; French Anderson; Lena A Basile
Journal:  Genet Vaccines Ther       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.